ciglitazone has been researched along with Hyperlipemia in 2 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hofnagel, O | 1 |
| Engel, T | 1 |
| Severs, NJ | 1 |
| Robenek, H | 1 |
| Buers, I | 1 |
| Fu, J | 1 |
| Oveisi, F | 1 |
| Gaetani, S | 1 |
| Lin, E | 1 |
| Piomelli, D | 1 |
2 other studies available for ciglitazone and Hyperlipemia
| Article | Year |
|---|---|
SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cell Adhesion; Cells, Cultured; Chemokine CXCL16 | 2011 |
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
Topics: Animals; Body Weight; Butyrates; CD36 Antigens; Cholesterol; Coenzyme A Ligases; Eating; Endocannabi | 2005 |